TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
ProPharma Group Sweden AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
88,370
|
97,052
|
92,174 |
| Financial expenses |
1,519
|
1,465
|
13 |
| Earnings before taxes |
-21,209
|
-3,708
|
-4,713 |
| EBITDA |
-19,612
|
-4,309
|
-4,535 |
| Total assets |
51,567
|
67,429
|
49,761 |
| Current assets |
51,142
|
66,897
|
49,127 |
| Current liabilities |
33,442
|
44,996
|
25,351 |
| Equity capital |
18,125
|
19,759
|
21,288 |
| - share capital |
103
|
101
|
95 |
| Employees (average) |
55
|
57
|
65 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
35.1%
|
29.3%
|
42.8% |
| Turnover per employee |
1,607
|
1,703
|
1,418 |
| Profit as a percentage of turnover |
-24.0%
|
-3.8%
|
-5.1% |
| Return on assets (ROA) |
-38.2%
|
-3.3%
|
-9.4% |
| Current ratio |
152.9%
|
148.7%
|
193.8% |
| Return on equity (ROE) |
-117.0%
|
-18.8%
|
-22.1% |
| Change turnover |
-10,433
|
-1,661
|
597 |
| Change turnover % |
-11%
|
-2%
|
1% |
| Chg. No. of employees |
-2
|
-8
|
8 |
| Chg. No. of employees % |
-4%
|
-12%
|
14% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.